Latest & greatest articles for levofloxacin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levofloxacin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levofloxacin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levofloxacin

1. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. (PubMed)

Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. Bacteremia causes considerable morbidity among children with acute leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). There are limited data on the effect of antibiotic prophylaxis in children.To determine the efficacy and risks of levofloxacin prophylaxis in children receiving intensive chemotherapy (...) for acute leukemia or undergoing HSCT.In this multicenter, open-label, randomized trial, patients (6 months-21 years) receiving intensive chemotherapy were enrolled (September 2011-April 2016) in 2 separate groups-acute leukemia, consisting of acute myeloid leukemia or relapsed acute lymphoblastic leukemia, and HSCT recipients-at 76 centers in the United States and Canada, with follow-up completed September 2017.Patients with acute leukemia were randomized to receive levofloxacin prophylaxis for 2

Full Text available with Trip Pro

2018 JAMA

2. Levofloxacin

Levofloxacin Top results for levofloxacin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for levofloxacin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial Proton pump inhibitor (PPI)-amoxicillin-fluoroquinolone triple therapy is recommended as a second-line treatment of Helicobacter pylori infection in the Maastricht V/Florence Consensus Report. However, the eradication rate of this standard (...) salvage treatment is suboptimal. The objective of this study is to compare the efficacy of esomeprazole-bismuth-tetracycline-levofloxacin therapy (TL quadruple therapy) and esomeprazole-amoxicillin-levofloxacin triple therapy (AL triple therapy) in rescue treatment for H. pylori infection.Consecutive H. pylori-infected subjects after failure of first-line therapies were randomly allocated to receive either TL quadruple therapy (esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s

2017 EvidenceUpdates

4. Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin (PubMed)

Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin To develop bromelain capped gold nanoparticles (BRN capped Au-NPs) as the effective drug delivery carriers of the antibiotic levofloxacin (LvN) and evaluate antibacterial potential of its bioconjugated form compared to pure LvN. BRN capped Au-NPs were synthesized by in vitro method and bioconjugated to LvN using 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide as activator

Full Text available with Trip Pro

2016 EXCLI journal

5. Levofloxacin (Quinsair) - chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Levofloxacin (Quinsair) - chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Final Appraisal Recommendation Advice No: 3016 – November 2016 Levofloxacin (Quinsair ® ) 240 mg nebuliser solution Submission by Horizon Pharma plc Additional note(s): • AWMSG considered that levofloxacin (Quinsair ® ) satisfied the AWMSG criteria for appraising orphan and ultra-orphan medicines and medicines developed specifically for rare diseases. In reaching (...) for review every three years. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3016: Levofloxacin (Quinsair ® ) 240 mg nebuliser solution. November 2016. Recommendation of AWMSG Levofloxacin (Quinsair ® ) is recommended as an option for restricted use within NHS Wales. Levofloxacin (Quinsair ® ) should be restricted for use as a third-line therapy

2016 All Wales Medicines Strategy Group

6. Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study. (PubMed)

Aspirin and levofloxacin for the prevention of the occurrence of prostate cancer or transformation to castration-resistant prostate cancer: a two-part, open-label, randomised, controlled study.

2016 Lancet

7. Levofloxacin (Quinsair)

Levofloxacin (Quinsair) Levofloxacin | CADTH.ca Find the information you need Levofloxacin Levofloxacin Last Updated: May 2, 2016 Result type: Reports Project Number: SR0493-000 Product Line: Generic Name: Levofloxacin Brand Name: Quinsair Manufacturer: Raptor Pharmaceuticals Inc. Indications: Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections Submission Type: New Project Status: Complete Date Recommendation Issued: November 21, 2016 Recommendation Type: Reimburse

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

8. Randomised controlled trial: In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal

Randomised controlled trial: In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal In H. pylori- infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage (...) patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal Article Text Therapeutics/Prevention Randomised controlled trial In H. pylori - infected patients second-line treatment with sequential levofloxacin therapy was more effective than levofloxacin triple therapy but was still suboptimal Adrian G McNicholl , Javier P Gisbert Statistics from Altmetric.com Commentary on : Liou JM , Bair MJ , Chen CC , et al

2016 Evidence-Based Medicine (Requires free registration)

9. Tavanic (levofloxacin), fluoroquinolone - the treatment of complicated skin and soft tissue infections

Tavanic (levofloxacin), fluoroquinolone - the treatment of complicated skin and soft tissue infections TAVANIC SUMMARY CT12590

2015 Haute Autorite de sante

10. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). (PubMed)

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Treatment of complicated urinary-tract infections is challenging due to rising antimicrobial resistance. We assessed the efficacy and safety of ceftolozane-tazobactam, a novel antibacterial with Gram-negative activity, in the treatment of patients with complicated lower-urinary-tract infections (...) or pyelonephritis.ASPECT-cUTI was a randomised, double-blind, double-dummy, non-inferiority trial done in 209 centres in 25 countries. Between July, 2011, and September, 2013, hospital inpatients aged 18 years or older who had pyuria and a diagnosis of a complicated lower-urinary-tract infection or pyelonephritis were randomly assigned in a 1:1 ratio to receive intravenous 1·5 g ceftolozane-tazobactam every 8 h or intravenous high-dose (750 mg) levofloxacin once daily for 7 days. The randomisation schedule

2015 Lancet

11. Quinsair - levofloxacin

Quinsair - levofloxacin 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 18 December 2014 EMA/CHMP/676680/2014, Corr. 1 Committee for Medicinal Products for Human Use (CHMP) Assessment report Quinsair International non-proprietary name: levofloxacin Procedure No. EMEA/H/C/002789/0000 Note Assessment report as adopted by the CHMP (...) with all information of a commercially confidential nature deleted. EMA/CHMP/676680/2014 Page 2/106 Administrative information Name of the medicinal product: Quinsair Applicant: Aptalis Pharma SAS Route de Bû la Prévôté 78550 Houdan FRANCE Active substance: Levofloxacin hemihydrate International Non-proprietary Name / Common Name: Levofloxacin Pharmaco-therapeutic group (ATC Code): Levofloxacin (J01MA12) Therapeutic indication: Quinsair is indicated for the management of chronic pulmonary infections

2015 European Medicines Agency - EPARs

12. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. (PubMed)

Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. BK virus infection is a significant complication of modern immunosuppression used in kidney transplantation. Viral reactivation occurs first in the urine (BK viruria) and is associated with a high risk of transplant failure. There are currently no therapies to prevent or treat BK virus infection. Quinolone antibiotics have antiviral properties against BK virus but efficacy at preventing (...) this infection has not been shown in prospective controlled studies.To determine if levofloxacin can prevent BK viruria in kidney transplant recipients.Double-blind, placebo-controlled randomized trial involving 154 patients who received a living or deceased donor kidney-only transplant in 7 Canadian transplant centers between December 2011 and June 2013.Participants were randomly assigned to receive a 3-month course of levofloxacin (500 mg/d; n = 76) or placebo (n = 78) starting within 5 days after

Full Text available with Trip Pro

2014 JAMA

13. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. (PubMed)

Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. BK virus infection is a significant complication of modern immunosuppression used in kidney transplantation. Viral reactivation occurs first in the urine (BK viruria) and is associated with a high risk of transplant failure. There are currently no therapies to prevent or treat BK virus infection. Quinolone antibiotics have antiviral properties against BK virus but efficacy at preventing (...) this infection has not been shown in prospective controlled studies.To determine if levofloxacin can prevent BK viruria in kidney transplant recipients.Double-blind, placebo-controlled randomized trial involving 154 patients who received a living or deceased donor kidney-only transplant in 7 Canadian transplant centers between December 2011 and June 2013.Participants were randomly assigned to receive a 3-month course of levofloxacin (500 mg/d; n = 76) or placebo (n = 78) starting within 5 days after

Full Text available with Trip Pro

2014 JAMA

14. Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial (PubMed)

Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial BK virus reactivation in kidney transplant recipients can lead to progressive allograft injury. Reduction of immunosuppression remains the cornerstone of treatment for active BK infection. Fluoroquinolone antibiotics are known to have in vitro antiviral properties, but the evidence for their use in patients with BK viremia is inconclusive. The objective of the study (...) was to determine the efficacy of levofloxacin in the treatment of BK viremia.Enrollment in this prospective, multicenter, double-blinded, placebo-controlled trial occurred from July 2009 to March 2012. Thirty-nine kidney transplant recipients with BK viremia were randomly assigned to receive levofloxacin, 500 mg daily, or placebo for 30 days. Immunosuppression in all patients was adjusted on the basis of standard clinical practices at each institution. Plasma BK viral load and serum creatinine were measured

Full Text available with Trip Pro

2014 EvidenceUpdates

15. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis (PubMed)

Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking.To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB.In this prospective

2014 EvidenceUpdates

16. Levofloxacin: some indications restricted

Levofloxacin: some indications restricted Levofloxacin: some indications restricted - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Levofloxacin: some indications restricted Levofloxacin (a fluoroquinolone antibiotic) is unfavourable as first-line treatment for several indications. Published 11 December 2014 From: Therapeutic area: , , , Article date: September 2012 Levofloxacin (a fluoroquinolone antibiotic) may only be considered in the treatment of acute bacterial sinusitis (...) , acute exacerbation of chronic bronchitis, community acquired pneumonia or complicated skin and soft tissue infections when other medicines cannot be prescribed, or have been ineffective. This restriction resulted from a review of overall efficacy and safety data, which suggested that the safety profile of levofloxacin was unfavourable as first-line treatment for these indications. The risks contributing to this assessment included serious hepatotoxicity, cardiac arrhythmia, severe skin reactions

2012 MHRA Drug Safety Update

17. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial (PubMed)

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial Antimicrobial drug resistance is a major cause of the failure of Helicobacter pylori eradication and is largely responsible for the decline in eradication rate. Quadruple therapy has been suggested as a first-line regimen in areas with clarithromycin resistance rate >15%. This randomised trial aimed at evaluating the efficacy of a levofloxacin-containing (...) ; or (2) omeprazole 20 mg twice daily +amoxicillin 1 g twice daily followed by omeprazole 20 mg twice daily + levofloxacin 250 mg twice daily +tinidazole 500 mg twice daily; or (3) omeprazole 20 mg twice daily + amoxicillin 1 g twice daily followed by omeprazole 20 mg twice daily + levofloxacin 500 mg twice daily + tinidazole 500 mg twice daily. Antimicrobial resistance was assessed by the E-test. Efficacy, adverse events and costs were determined for each group.Eradication rates in the intention

2011 EvidenceUpdates

18. Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study (PubMed)

Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study Simple compound of Helicobacter pylori eradication therapy may improve drug compliance of patients. The aims of this study were to compare the efficacy and tolerability of a simple combination containing levofloxacin 7-day once-daily with standard twice-daily triple therapy.This was a prospective (...) , randomised, open-label trial. A total of 189 consecutive patients diagnosed with peptic ulcer and H. pylori infection were enrolled. Patients were randomly divided into two groups: LEC group--levofloxacin 500 mg, esomeprazole 40 mg and clarithromycin 500 mg once daily for 7 days; AEC group--amoxicillin 1 g, esomeprazole 40 mg and clarithromycin 500 mg twice daily for 7 days.There were 90 patients in the LEC group and 99 patients in the AEC group. By intention-to-treat and per-protocol analysis, the H

2010 EvidenceUpdates

19. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. (PubMed)

Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Use of fluoroquinolones to treat paediatric cases of multidrug-resistant tuberculosis could affect the emergence of resistance to this class of drugs. Our aim was to estimate the incidence of, and risk factors for, invasive pneumococcal disease caused by fluoroquinolone-resistant Streptococcus pneumoniae (...) in children in South Africa.21,521 cases of invasive pneumococcal disease were identified by active national surveillance between 2000 and 2006, with enhanced surveillance at 15 sentinel hospitals in seven provinces introduced in 2003. We screened 19,404 isolates (90% of cases) for ofloxacin resistance and measured levofloxacin minimum inhibitory concentrations (MICs) for all isolates that were ofloxacin resistant. Non-susceptibility to levofloxacin was defined as an MIC of 4 mg/L or more. Nasopharyngeal

2008 Lancet

20. Levofloxacin for acute exacerbations of chronic bronchitis

Levofloxacin for acute exacerbations of chronic bronchitis Levofloxacin for acute exacerbations of chronic bronchitis | Therapeutics Initiative Independent Healthcare Evidence > > Levofloxacin for acute exacerbations of chronic bronchitis Background Information of the Condition Chronic bronchitis is a subset of chronic obstructive pulmonary disease defined by a productive cough for at least 3 months in duration in each of 2 consecutive years, which may include an acute exacerbation of increased (...) sputum production and purulence, and increased dyspnea. An increased respiratory rate and wheezing, lethargy and elevated temperature are usually indicative of an acute exacerbation of chronic bronchitis, which is usually caused by a virus. Measurement of expiratory flow volume is recommended along with oxygen saturation in moderate to severe cases, whereas sputum cultures are not routinely recommended. Drug (Product Monograph) , Category: Levofloxacin, the L-isomer of the racemate ofloxacin

2008 Therapeutics Letter